Takeda Plans US Investment But Sees Little Impact From Tariffs
The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.
The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.